ArticleBMC cancer2025
Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Advances in translational lung cancer research in 2025: a narrative review.Translational lung cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe C797S mutation is a prevalent resistance mechanism to third-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). Management of C797S-positive NSCLC encompasses diverse approaches, including targeted and chemotherapy-based therapies.
methodsThis analysis included 44 C797S mutant NSCLC patients, all of whom had developed resistance to third-generation EGFR TKIs and had comprehensive treatment and survival data available.
resultsIn the collective C797S + NSCLC cohort, chemotherapy-based therapies demonstrated superior progression-free survival (PFS) relative to non-chemotherapy treatments (5.5 versus 3.4 months, p = 0.014). Specific median PFS outcomes for various regimens were as follows: chemotherapy plus bevacizumab, 6.4 months; chemotherapy with both immunotherapy and bevacizumab, 6.1 months; and chemotherapy with immunotherapy, 4.2 months; chemotherapy alone, 3.8 months. Monotherapy and combinations involving anlotinib, different generations of EGFR TKIs, brigatinib with cetuximab, and immunotherapy alone ranged from 3.5 to 1.5 months. Among T790M+/C797S + cis patients, those receiving chemotherapy-based regimens experienced longer PFS compared to those treated with brigatinib and cetuximab (6.0 versus 2.9 months, p = 0.018). The T790M-/C797S + subgroup saw greater PFS benefits from EGFR TKI-based therapies compared to chemotherapy-based therapies (5.8 versus 4.8 months, p = 0.043).
conclusionsTo date, chemotherapy-based treatments remain the standard of care for C797S + NSCLC patients resistant to third-generation EGFR TKIs. However, for T790M-/C797S + patients received a third-generation EGFR TKI as first-line therapy, EGFR-TKI rechallenge, involving a combination of first and third-generation EGFR TKIs or first/second-generation TKIs, may be an optimal strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.